Precigen (PGEN) announces it has seen “robust uptake” in usage of Papzimeos since launching the immunotherapy in August 2025. Additionally, the company announced that the Centers for Medicare and Medicaid Services assigned J-code J3404 to the therapy effective April 1, 2026, which will streamline reimbursement and broaden access to the treatment.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PGEN:
- Papzimeos: Accelerating Commercial Ramp, Larger-Than-Expected RRP Market, and Strong 2026 Revenue Outlook Support Buy Rating
- Precigen Earnings Call Signals Powerful Launch Momentum
- Precigen jumps on Q1 outlook despite earnings miss
- Buy Rating on Papzimeos Driven by Strong Early Launch Traction, Multi‑Year Growth Catalysts, and Long-Term IP Protection
- Precigen price target raised to $10 from $9 at H.C. Wainwright